CsA-Sensitive Rh123 Efflux Is Maintained During and After Treatment With VAD
| . | % of Subset With CsA-Sensitive . | |
|---|---|---|
| . | Rh123 Efflux . | |
| . | PBMC B Cells (%) . | BM Plasma Cells (%) . |
| Patient no. 1 | ||
| At diagnosis | 3 | |
| Mo 3/VAD | 62 | |
| Mo 5/VAD | 45 | |
| Mo 7/VAD | 47 | |
| Mo 9/off | 70 | |
| Patient no. 2 | ||
| 2 cycles of VAD/unresponsive | ||
| Mo 10/Ifn | 30 | |
| Mo 12/IL-2 + Ifn | 26 | |
| Mo 13/ante-mortem | 7 | |
| Patient no. 3 | ||
| Mo 4/VAD | 41 | |
| Mo 8/VAD | 63 | |
| Mo 11/VAD | 59 | |
| Mo 18/off | 67 | |
| Patient no. 4 | ||
| VAD | ||
| Mo 10/relapse | 63 | 9 |
| Mo 12/off | 65 | |
| Mo 16/M/P | 17 | |
| Mo 26/death | ||
| Patient no. 5 | ||
| Mo 2/VAD | 76 | |
| Mo 4/VAD | 60 | |
| Mo 5/VAD | 49 | |
| Patient no. 6 | ||
| At diagnosis | 72 | |
| Mo 4/untreated | 60 | |
| Mo 5/untreated | 81 | |
| Patient no. 7 | ||
| Mo 4/M/P | 78 | |
| Mo 9/VAD | 96 | |
| . | % of Subset With CsA-Sensitive . | |
|---|---|---|
| . | Rh123 Efflux . | |
| . | PBMC B Cells (%) . | BM Plasma Cells (%) . |
| Patient no. 1 | ||
| At diagnosis | 3 | |
| Mo 3/VAD | 62 | |
| Mo 5/VAD | 45 | |
| Mo 7/VAD | 47 | |
| Mo 9/off | 70 | |
| Patient no. 2 | ||
| 2 cycles of VAD/unresponsive | ||
| Mo 10/Ifn | 30 | |
| Mo 12/IL-2 + Ifn | 26 | |
| Mo 13/ante-mortem | 7 | |
| Patient no. 3 | ||
| Mo 4/VAD | 41 | |
| Mo 8/VAD | 63 | |
| Mo 11/VAD | 59 | |
| Mo 18/off | 67 | |
| Patient no. 4 | ||
| VAD | ||
| Mo 10/relapse | 63 | 9 |
| Mo 12/off | 65 | |
| Mo 16/M/P | 17 | |
| Mo 26/death | ||
| Patient no. 5 | ||
| Mo 2/VAD | 76 | |
| Mo 4/VAD | 60 | |
| Mo 5/VAD | 49 | |
| Patient no. 6 | ||
| At diagnosis | 72 | |
| Mo 4/untreated | 60 | |
| Mo 5/untreated | 81 | |
| Patient no. 7 | ||
| Mo 4/M/P | 78 | |
| Mo 9/VAD | 96 | |
Abbreviations: IFn, interferon; M/P, melphalan prednisone.
The time points listed designate months post-diagnosis.